MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Ventilation defect percent (VDP) as measured by 129Xe-MRI
Study Overview
Brief Summary
This research study is looking at new ways of measuring the function of the lungs in patients with cystic fibrosis. This study is using the most advanced methods for measuring lung function including 2 tests called hyperpolarised gas magnetic resonance imaging (HP MRI) and multiple breath washout (MBW), to better understand changes in the lungs over time.
HP MRI involves taking pictures of the air in your lungs after breathing in a harmless gas (xenon). MBW is a breathing test used to calculate something called the lung clearance index (LCI).
By measuring these tests on the same day, alongside standard lung function tests, we aim to understand lung function in greater detail than ever before.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 1 Year to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Ventilation defect percent (VDP) as measured by 129Xe-MRI
Time Frame: Up to 3 years, depending on cohort.
The primary endpoint will be changes in the 129Xe-MRI metric; ventilation defect percent (VDP) between study visits.
Secondary Outcomes
- XeMRI outcome measures - Ventilation Heterogeneity Index(up to 3 years)
- XeMRI outcome measures - individual defects(up to 3 years)
- XeMRI outcome measures - reversibility index(up to 3 years)
- Lung function metrics - LCI(Up to 3 years)
- Lung function metrics - Scond (from MBW).(Up to 3 years)
- Lung function metrics - Sacin (from MBW).(Up to 3 years)